Valeant Pharmaceuticals Intl (NYSE:VRX) (TSE:VRX) received a $20.00 price objective from equities research analysts at Deutsche Bank in a research note issued on Wednesday. The brokerage currently has a “buy” rating on the specialty pharmaceutical company’s stock. Deutsche Bank’s target price would indicate a potential upside of 25.31% from the company’s previous close.

A number of other equities analysts also recently commented on the company. Zacks Investment Research downgraded Valeant Pharmaceuticals Intl from a “hold” rating to a “strong sell” rating in a research report on Saturday, January 13th. HC Wainwright boosted their price objective on Valeant Pharmaceuticals Intl from $17.00 to $24.00 and gave the stock a “buy” rating in a research report on Tuesday, January 16th. Wells Fargo reissued a “sell” rating and set a $9.00 price objective on shares of Valeant Pharmaceuticals Intl in a research report on Tuesday, January 16th. TD Securities boosted their price objective on Valeant Pharmaceuticals Intl from $20.00 to $27.00 and gave the stock a “buy” rating in a research report on Friday, January 5th. Finally, Cantor Fitzgerald set a $25.00 price objective on Valeant Pharmaceuticals Intl and gave the stock a “buy” rating in a research report on Friday, January 19th. Seven analysts have rated the stock with a sell rating, ten have given a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $18.30.

How to Become a New Pot Stock Millionaire

VRX stock opened at $15.96 on Wednesday. Valeant Pharmaceuticals Intl has a 52-week low of $8.31 and a 52-week high of $24.43. The company has a market capitalization of $5,574.43, a PE ratio of 2.34, a PEG ratio of 0.33 and a beta of -0.28. The company has a debt-to-equity ratio of 4.25, a quick ratio of 0.87 and a current ratio of 1.11.

Valeant Pharmaceuticals Intl (NYSE:VRX) (TSE:VRX) last announced its quarterly earnings data on Wednesday, February 28th. The specialty pharmaceutical company reported $0.98 EPS for the quarter, topping the Zacks’ consensus estimate of $0.96 by $0.02. Valeant Pharmaceuticals Intl had a return on equity of 42.48% and a net margin of 27.56%. The business had revenue of $2.16 billion during the quarter, compared to the consensus estimate of $2.18 billion. During the same period in the previous year, the company posted $1.26 earnings per share. The business’s revenue for the quarter was down 10.0% on a year-over-year basis. research analysts predict that Valeant Pharmaceuticals Intl will post 3.12 EPS for the current year.

In other Valeant Pharmaceuticals Intl news, CFO Paul Herendeen bought 15,000 shares of the firm’s stock in a transaction that occurred on Tuesday, March 13th. The stock was purchased at an average price of $16.10 per share, for a total transaction of $241,500.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Joseph C. Papa bought 30,000 shares of the firm’s stock in a transaction that occurred on Tuesday, March 13th. The shares were acquired at an average price of $16.05 per share, with a total value of $481,500.00. The disclosure for this purchase can be found here. In the last 90 days, insiders have purchased 7,121,629 shares of company stock valued at $109,702,487. 5.87% of the stock is owned by company insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of VRX. Renaissance Technologies LLC lifted its stake in Valeant Pharmaceuticals Intl by 122.8% in the fourth quarter. Renaissance Technologies LLC now owns 10,651,189 shares of the specialty pharmaceutical company’s stock valued at $221,332,000 after buying an additional 5,870,689 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in Valeant Pharmaceuticals Intl by 327.6% in the third quarter. Dimensional Fund Advisors LP now owns 4,472,185 shares of the specialty pharmaceutical company’s stock valued at $64,086,000 after buying an additional 3,426,410 shares during the last quarter. Two Sigma Investments LP purchased a new stake in Valeant Pharmaceuticals Intl in the fourth quarter valued at approximately $57,221,000. Two Sigma Advisers LP lifted its stake in Valeant Pharmaceuticals Intl by 7,294.2% in the fourth quarter. Two Sigma Advisers LP now owns 1,428,418 shares of the specialty pharmaceutical company’s stock valued at $29,683,000 after buying an additional 1,409,100 shares during the last quarter. Finally, Schroder Investment Management Group lifted its stake in Valeant Pharmaceuticals Intl by 2,951.5% in the fourth quarter. Schroder Investment Management Group now owns 1,113,800 shares of the specialty pharmaceutical company’s stock valued at $29,182,000 after buying an additional 1,077,300 shares during the last quarter. Institutional investors own 50.09% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece of content was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/valeant-pharmaceuticals-intl-vrx-pt-set-at-20-00-by-deutsche-bank-2/1959170.html.

About Valeant Pharmaceuticals Intl

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Analyst Recommendations for Valeant Pharmaceuticals Intl (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals Intl Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl and related companies with MarketBeat.com's FREE daily email newsletter.